Aristada, also known by its generic name aripiprazole lauroxil, is an injectable medication used for the treatment of schizophrenia and bipolar I disorder [1]. It is a long-acting injectable (LAI) formulation of aripiprazole [2].
How does Aristada work for schizophrenia?
Aristada works by affecting the activity of certain neurotransmitters in the brain, primarily dopamine and serotonin [3]. By modulating these chemical messengers, it helps to improve thought processes and behavior in individuals experiencing psychosis [3]. The lauroxil ester is a prodrug that is slowly hydrolyzed in the body to release active aripiprazole over an extended period, allowing for less frequent dosing compared to oral medications [2].
What is the difference between Aristada and oral aripiprazole?
The primary difference between Aristada and oral aripiprazole lies in their delivery method and duration of action [2]. Aristada is an injectable formulation administered intramuscularly, providing a continuous release of the medication over weeks or months, depending on the specific dosage regimen [4]. Oral aripiprazole is taken by mouth daily [5]. The injectable form can be beneficial for patients who have difficulty adhering to daily oral medication schedules or who experience symptom exacerbations between doses [2].
When does Aristada's patent expire?
Information regarding the specific patent expiration dates for Aristada is dynamic and subject to legal challenges and new patent filings. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Aristada [6]. Generally, for extended-release injectable formulations like Aristada, patent protection can extend beyond the standard patent life of the original molecule due to formulation and delivery innovations [7].
Who manufactures Aristada?
Aristada was developed by Alkermes plc [1].
What are the potential side effects of Aristada?
Common side effects associated with Aristada can include insomnia, headache, injection site pain, constipation, nausea, and weight gain [1]. More serious, though less common, side effects can include tardive dyskinesia (involuntary movements), neuroleptic malignant syndrome (a rare but potentially fatal condition), and metabolic changes such as hyperglycemia and dyslipidemia [1][3]. Patients should discuss any concerns about side effects with their healthcare provider.
How is Aristada administered?
Aristada is administered as an intramuscular injection. The frequency of administration depends on the prescribed dose and formulation, with options for monthly or every-other-month injections [4]. The injection is typically given by a healthcare professional [4].
Can Aristada be used for other mental health conditions?
While Aristada is approved for schizophrenia and bipolar I disorder [1], aripiprazole, the active ingredient, is also used off-label for other conditions such as major depressive disorder and irritability associated with autism spectrum disorder [5]. However, the specific approvals for Aristada are for schizophrenia and bipolar I disorder.
What is the mechanism of action of aripiprazole?
Aripiprazole, the active metabolite of Aristada, is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors [3][5]. This unique mechanism helps to stabilize the dopaminergic and serotonergic systems, contributing to its efficacy in treating psychotic and mood disorders [3].
What are the risks associated with long-acting injectable antipsychotics?
Risks associated with long-acting injectable antipsychotics like Aristada are similar to those of oral antipsychotics, but the prolonged release can also influence side effect profiles and management [2]. These risks include movement disorders (like tardive dyskinesia), metabolic changes, and neurological effects [1][3]. It is crucial for patients to be monitored by a healthcare professional for these potential adverse events [1].
What are alternative treatments for schizophrenia?
Alternative treatments for schizophrenia include other antipsychotic medications, both oral and injectable, as well as psychosocial interventions [8]. The choice of treatment depends on individual patient needs, response to medication, side effect profiles, and adherence considerations [8].
Sources
1. https://www.drugpatentwatch.com/aristada
2. https://www.drugpatentwatch.com/